This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. ITRM, FBLG, ONCY, VRCA, RFL, CUE, RVPH, XLO, ATNM, and SPROShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Iterum Therapeutics (ITRM), FibroBiologics (FBLG), Oncolytics Biotech (ONCY), Verrica Pharmaceuticals (VRCA), Rafael (RFL), Cue Biopharma (CUE), Reviva Pharmaceuticals (RVPH), Xilio Therapeutics (XLO), Actinium Pharmaceuticals (ATNM), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Iterum Therapeutics FibroBiologics Oncolytics Biotech Verrica Pharmaceuticals Rafael Cue Biopharma Reviva Pharmaceuticals Xilio Therapeutics Actinium Pharmaceuticals Spero Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation. Is ITRM or IMRN more profitable? Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -90.85% Immuron N/A N/A N/A Does the media favor ITRM or IMRN? In the previous week, Iterum Therapeutics had 3 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Iterum Therapeutics and 1 mentions for Immuron. Iterum Therapeutics' average media sentiment score of 0.97 beat Immuron's score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive Immuron Neutral Does the MarketBeat Community favor ITRM or IMRN? Immuron received 47 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.87% of users gave Immuron an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% ImmuronOutperform Votes18867.87% Underperform Votes8932.13% Which has better earnings and valuation, ITRM or IMRN? Immuron has higher revenue and earnings than Iterum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$1.31-0.84Immuron$3.21M3.49-$4.55MN/AN/A Do institutionals and insiders believe in ITRM or IMRN? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate ITRM or IMRN? Iterum Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 354.55%. Immuron has a consensus target price of $5.00, indicating a potential upside of 160.42%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ITRM or IMRN? Iterum Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. SummaryIterum Therapeutics beats Immuron on 6 of the 11 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$6.85B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E RatioN/A7.4422.6918.83Price / Sales3.49257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book1.326.576.794.33Net Income-$4.55M$143.14M$3.22B$247.97M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.5582 of 5 stars$1.92-4.0%$5.00+160.4%-24.4%$11.03M$3.21M0.00N/AShort Interest ↑ITRMIterum Therapeutics2.525 of 5 stars$1.26flat$5.00+296.8%-30.4%$43.57MN/A-0.9610Short Interest ↓Positive NewsGap UpFBLGFibroBiologics2.8627 of 5 stars$1.14-7.0%$13.00+1,045.4%-85.0%$42.83MN/A-3.3410Short Interest ↓Gap UpONCYOncolytics Biotech1.2468 of 5 stars$0.57+2.5%$4.33+660.2%-53.0%$42.80MN/A-2.1130Upcoming EarningsNegative NewsVRCAVerrica Pharmaceuticals3.9045 of 5 stars$0.46-5.1%$9.50+1,947.0%-93.1%$42.60M$7.57M-0.2540Gap UpRFLRafael0.8075 of 5 stars$1.70-1.7%N/A-5.8%$42.35M$706,000.00-1.0220Short Interest ↓CUECue Biopharma3.911 of 5 stars$0.79+0.6%$3.00+279.7%-60.0%$41.73M$9.29M-0.8860Upcoming EarningsRVPHReviva Pharmaceuticals2.6349 of 5 stars$0.87+1.8%$10.00+1,048.9%-72.7%$40.68MN/A-0.785Short Interest ↑XLOXilio Therapeutics2.7525 of 5 stars$0.79-5.2%$4.00+409.4%-28.6%$40.65M$6.34M-0.4670News CoverageGap DownATNMActinium Pharmaceuticals1.3202 of 5 stars$1.30-0.8%$7.40+469.2%N/A$40.56M$81,000.00-0.9430Analyst RevisionGap DownSPROSpero Therapeutics4.2162 of 5 stars$0.71-2.1%$5.00+604.2%-59.8%$39.69M$27.40M10.14150Short Interest ↑ Related Companies and Tools Related Companies ITRM Competitors FBLG Competitors ONCY Competitors VRCA Competitors RFL Competitors CUE Competitors RVPH Competitors XLO Competitors ATNM Competitors SPRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
